Glimepiride
Amaryl
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 2 diabetes mellitus — adjunct to diet and exercise | Adults | Monotherapy, combination with metformin, or combination with insulin | FDA Approved |
Glimepiride is FDA-approved for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It can be used as monotherapy when metformin is insufficient or contraindicated, or combined with metformin or insulin for patients requiring intensification. The ADA Standards of Care (2023) position sulfonylureas as viable second-line agents, and among the sulfonylureas, glimepiride is generally preferred over glyburide due to its lower hypoglycemia risk and convenient once-daily dosing. Glimepiride is not effective in type 1 diabetes or diabetic ketoacidosis.
Neonatal diabetes (KCNJ11/ABCC8 mutations): Glimepiride, like other sulfonylureas, has been explored for neonatal diabetes caused by activating mutations in KATP channel genes. Evidence quality: Low (case reports and small series; glyburide is the more commonly studied agent in this setting).
Dosing
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — treatment-naive, initial monotherapy | 1–2 mg once daily | 1–4 mg once daily | 8 mg once daily | Give with breakfast; after reaching 2 mg, increase by 1–2 mg every 1–2 weeks based on glycemic response FDA PI: usual maintenance 1–4 mg/day |
| T2DM — hypoglycemia-prone (elderly, renal impairment, debilitated) | 1 mg once daily | Titrate conservatively | 8 mg once daily | Conservative titration; elderly are particularly susceptible; monitor blood glucose closely FDA PI |
| T2DM — add-on to metformin (inadequate control on metformin alone) | 1 mg once daily | Titrate per response | 8 mg once daily | Identify minimum effective dose of each drug to reduce hypoglycemia risk ADA 2023 recommends dual therapy if HbA1c remains above target on metformin monotherapy |
| T2DM — add-on to insulin (secondary failure on oral agents) | 8 mg once daily | 8 mg once daily | 8 mg once daily | Use when fasting glucose >150 mg/dL despite maximum oral therapy; start low-dose insulin (e.g., 8–10 units) and titrate based on glucose FDA PI; insulin dose adjustments driven by SMBG |
| T2DM — switching from another sulfonylurea | 1–2 mg once daily | Titrate per response | 8 mg once daily | Max starting dose 2 mg; if switching from chlorpropamide, observe for overlapping effect for 1–2 weeks No transition period needed for shorter-acting agents |
| T2DM — renal impairment | 1 mg once daily | Conservative titration | 8 mg once daily | Active metabolite M1 accumulates significantly in severe renal impairment (AUC increased 2.3-fold when CrCl <20 mL/min); M2 AUC increases 8.6-fold FDA PI: single-dose renal study |
Glimepiride is generally preferred over glyburide within the sulfonylurea class (AACE/ACE 2019, ADA 2023). It has a shorter duration of action, lower hypoglycemia risk (2–4% confirmed episodes vs. 20–30% with glyburide), once-daily convenience, and more predictable pharmacokinetics. Unlike glyburide, glimepiride dissociates more rapidly from the sulfonylurea receptor, which may preserve some degree of glucose-dependent insulin secretion and contribute to its safer hypoglycemia profile.
Pharmacology
Mechanism of Action
Glimepiride lowers blood glucose primarily by stimulating insulin release from functioning pancreatic beta cells. It binds to the sulfonylurea receptor 1 (SUR1) subunit of ATP-sensitive potassium (KATP) channels on the beta-cell membrane, causing channel closure, membrane depolarization, and subsequent calcium-mediated insulin exocytosis. A distinguishing feature of glimepiride compared to older sulfonylureas is its faster association and dissociation kinetics at the receptor, which may partially preserve the physiological suppression of insulin secretion during hypoglycemia. There is also evidence for extrapancreatic effects, including enhanced peripheral glucose uptake through increased GLUT4 translocation and modulation of intracellular insulin signaling, though their clinical relevance remains uncertain.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Complete (~100% bioavailable); Tmax 2–3 h; food decreases Cmax by ~8% but does not significantly affect AUC | Reliable and predictable absorption; take with breakfast for consistency and to reduce fasting hypoglycemia risk |
| Distribution | Vd ~8.8 L (IV data); >99.5% protein bound (primarily albumin) | Extensive protein binding; displacement interactions are theoretically possible but clinically uncommon due to low Vd |
| Metabolism | Hepatic via CYP2C9; M1 (cyclohexyl hydroxymethyl, ~1/3 activity of parent) → M2 (carboxyl derivative, inactive) | CYP2C9 polymorphisms (*2, *3) can markedly reduce clearance (up to 4-fold higher AUC in *1/*3 carriers); CYP2C9 inhibitors increase glimepiride exposure |
| Elimination | t½ ~5–8 h (dose-dependent, across 1–8 mg); ~60% urine, ~40% feces (as metabolites); no unchanged drug in urine | Linear pharmacokinetics across the therapeutic range; no accumulation with multiple dosing; renal impairment increases M1 and M2 exposure, not parent drug clearance |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypoglycemia (symptomatic, all severity) | 4–19.7% | Dose-dependent: 4% at 1 mg, 17% at 4 mg, 16% at 8 mg vs. 0% placebo in 14-week trial; overall 19.7% vs. 3.2% placebo in 22-week trial (FDA PI). Confirmed hypoglycemia (BG <60 mg/dL) was 0.9–1.7% in long-term controlled trials. Significantly lower than glyburide (2–4% vs. 20–30%) |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | ≥5% | Reported more frequently than placebo in 11 pooled trials (FDA PI); often transient |
| Dizziness | ≥5% | May be related to blood glucose fluctuations; usually improves with dose stabilization |
| Nausea | ≥5% | Dose-related; typically self-limiting; take consistently with food |
| Asthenia | ≥5% | General weakness/fatigue; reported among the most common adverse reactions (FDA PI) |
| Accidental injury | 5.4% | Vs. 3.4% placebo; insufficient data to determine association with hypoglycemia (FDA PI) |
| Weight gain | Common (class effect) | Sulfonylurea class effect; insulin secretion promotes energy storage; generally 1–3 kg over months |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hypoglycemia (loss of consciousness, seizure) | 0.9–1.7% | Any time; higher during titration and with interacting drugs | IV dextrose; octreotide for rebound hypoglycemia from endogenous insulin stimulation; monitor 24–48 h; dose reduction or discontinuation |
| Anaphylaxis / angioedema / Stevens-Johnson syndrome | Very rare (postmarketing) | Days to weeks after initiation | Discontinue immediately; treat reaction; do not rechallenge; switch to non-sulfonylurea |
| Hemolytic anemia (with or without G6PD deficiency) | Rare (postmarketing) | Variable | Obtain CBC and reticulocyte count; discontinue glimepiride; consider G6PD testing; use non-sulfonylurea alternative |
| Hepatitis / cholestatic jaundice / liver failure | Rare (postmarketing) | Weeks to months | Discontinue; monitor LFTs; may progress to liver failure if not recognized. ALT >2× ULN occurred in 1.9% vs. 0.8% placebo in trials |
| Hyponatremia / SIADH | Very rare | Weeks to months | Check sodium; most cases involved patients on other medications known to cause hyponatremia; discontinue if confirmed |
| Blood dyscrasias (agranulocytosis, aplastic anemia, pancytopenia) | Very rare (<0.1%) | Weeks to months | Obtain CBC; discontinue; hematology referral if indicated |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Hypoglycemia | <1% | All events in pivotal trials were self-treated; severe hypoglycemia requiring discontinuation is uncommon |
| GI adverse effects | <2% | Nausea or diarrhea severe enough to discontinue |
| Allergic reactions | <1% | Pruritus, urticaria; may resolve despite continued therapy in some cases |
Although glimepiride has a significantly lower hypoglycemia risk than glyburide, all sulfonylureas can cause clinically significant low blood sugar. In overdose settings, octreotide (a somatostatin analogue) is preferred over repeated dextrose boluses, because dextrose can trigger further endogenous insulin release from the sulfonylurea-stimulated beta cells, creating a cycle of recurrent hypoglycemia. For routine mild episodes, the standard 15 g fast-acting carbohydrate “rule of 15” approach applies.
Drug Interactions
Glimepiride is metabolized primarily by CYP2C9. It is highly protein bound (>99.5%) but this binding has not been shown to produce clinically important displacement interactions with commonly co-prescribed drugs. Key interactions relate to CYP2C9 modulation, glucose-metabolism interference, and absorption effects.
Multiple drug classes can antagonize glimepiride’s glucose-lowering effect by promoting hyperglycemia. These include thiazide diuretics, corticosteroids, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, isoniazid, and phenothiazines. When starting or stopping any of these agents, blood glucose should be monitored more closely and the glimepiride dose adjusted accordingly (FDA PI).
Monitoring
-
Blood Glucose (Fasting & Pre-Prandial)
Baseline, during titration, regularly thereafter
Routine SMBG is essential during dose titration and any change in clinical circumstances (illness, new medications, dietary changes). Target per individualized goals. -
HbA1c
Baseline, then every 3–6 months
Routine Assess glycemic control and determine if therapy needs intensification or de-intensification. Individualize targets (ADA: typically <7%; more relaxed in elderly/frail). -
Renal Function (eGFR, Creatinine)
Baseline, then at least annually
Routine Active metabolite M1 accumulates in renal impairment (2.3-fold AUC increase at CrCl <20 mL/min). Consider dose reduction or switching to glipizide (preferred SU in CKD) or a non-sulfonylurea alternative if eGFR declines significantly. -
Hepatic Function (LFTs)
Baseline; repeat if symptoms arise
Trigger-Based ALT >2× ULN in 1.9% of patients vs. 0.8% placebo. Obtain LFTs if jaundice, unexplained fatigue, or RUQ pain develops. Postmarketing hepatitis reports mandate prompt assessment. -
Complete Blood Count
As clinically indicated
Trigger-Based Hemolytic anemia (with or without G6PD deficiency), agranulocytosis, and aplastic anemia are rare but serious. Check if unexplained bruising, pallor, or fever develops. -
Body Weight
Every visit
Routine Weight gain is a class effect. Reassess treatment plan if weight gain becomes clinically problematic and consider agents with weight-neutral or weight-loss properties.
Contraindications & Cautions
Absolute Contraindications
- Type 1 diabetes mellitus — requires functioning beta cells; ineffective in insulin-dependent disease
- Diabetic ketoacidosis (DKA) — requires insulin therapy
- Known hypersensitivity to glimepiride or any component
- Hypersensitivity to sulfonamide derivatives — cross-sensitivity possible (FDA PI)
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment (CrCl <20 mL/min) — significant accumulation of active M1 metabolite (AUC increased 2.3-fold) and inactive M2 (8.6-fold); consider non-sulfonylurea alternative
- Severe hepatic disease — impaired CYP2C9 metabolism can nearly double glimepiride Cmax; reduced gluconeogenic reserve compounds hypoglycemia risk
- G6PD deficiency — risk of hemolytic anemia; non-sulfonylurea alternative preferred; if glimepiride must be used, test G6PD and monitor hematology closely
Use with Caution
- Elderly patients — more susceptible to hypoglycemia; start at 1 mg and titrate conservatively; recognition of hypoglycemia may be impaired
- Moderate renal impairment — conservative titration and increased glucose monitoring
- Adrenal or pituitary insufficiency — impaired counter-regulatory hormones increase hypoglycemia susceptibility
- Debilitated, malnourished, or alcohol-misusing patients — depleted glycogen stores worsen hypoglycemia severity
- Patients on beta-blockers — may mask autonomic hypoglycemia warning signs
- Pregnancy — discontinue at least 2 weeks before expected delivery to reduce neonatal hypoglycemia risk
The UGDP study reported that patients treated with tolbutamide for 5–8 years had cardiovascular mortality approximately 2.5 times higher than the diet-alone group. Although this involved tolbutamide specifically, the FDA considers the warning applicable to the entire sulfonylurea class, including glimepiride, given their similar mechanisms of action. Patients should be informed of the potential risks and benefits of sulfonylurea therapy and of alternative treatment options. No clinical studies have established conclusive evidence of macrovascular risk reduction with glimepiride or any other antidiabetic drug.
Patient Counselling
Purpose of Therapy
Glimepiride helps control blood sugar in type 2 diabetes by stimulating the pancreas to release more of the body’s own insulin. It is used alongside a healthy diet and regular exercise. It does not cure diabetes but helps prevent long-term complications such as kidney damage, nerve problems, and vision loss when blood sugar is well controlled.
How to Take
Take glimepiride once daily with breakfast or the first main meal. Do not skip meals after taking the medication, as this significantly increases the risk of low blood sugar. If you are also taking colesevelam, take glimepiride at least 4 hours before it.
Sources
- AMARYL (glimepiride) Tablets — FDA-Approved Prescribing Information. Sanofi-Aventis. Revised December 2018. FDA Label (PDF) Primary regulatory source for all dosing, pharmacokinetics, adverse reactions, and contraindications for glimepiride.
- Glimepiride Tablets — FDA-Approved Prescribing Information. DailyMed / NLM. DailyMed Current generic label with identical clinical content; includes Table 1 adverse event data from 11 pooled placebo-controlled trials.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. DOI Landmark trial establishing microvascular benefit of intensive glucose control with sulfonylureas; foundation for sulfonylurea use in T2DM.
- Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–394. DOI Meta-analysis providing evidence that glimepiride and other non-glyburide sulfonylureas have lower hypoglycemia risk than glyburide.
- Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily glimepiride and gliclazide MR in type 2 diabetes. Eur J Clin Invest. 2004;34(8):535–542. DOI Large RCT comparing glimepiride to gliclazide MR; demonstrated comparable efficacy with glimepiride achieving slightly better HbA1c reduction.
- ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2023. Diabetes Care. 2023;46(Suppl 1):S140–S157. DOI ADA 2023 Standards of Care positioning sulfonylureas as second-line agents; notes preference for glimepiride or glipizide over glyburide.
- Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm — 2019 Executive Summary. Endocr Pract. 2019;25(1):69–100. DOI AACE/ACE guideline noting glimepiride as a preferred sulfonylurea over glyburide for lower hypoglycemia risk.
- Müller G, Hartz D, Pünter J, Ökonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta. 1994;1191(2):267–277. DOI Defines the faster on/off receptor kinetics of glimepiride versus glyburide at the SUR1 receptor, explaining the differential hypoglycemia profile.
- Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999;42(8):903–919. DOI Foundational review of K-ATP channel physiology explaining the molecular target of all sulfonylureas.
- Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72(3):326–332. DOI Demonstrates that CYP2C9*3 carriers have markedly higher glimepiride exposure, informing pharmacogenomic dosing considerations.
- Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39(12):1617–1624. DOI Key study showing active metabolite accumulation in renal impairment and the paradoxical increase in apparent clearance of parent drug due to altered protein binding.
- Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs. 1998;55(4):563–584. DOI Comprehensive review covering glimepiride pharmacology, clinical efficacy data, and positioning within the sulfonylurea class at the time of its approval.
- Hardin MD, Jacobs TF. Glimepiride. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. NCBI Bookshelf Concise clinical review integrating current ADA guidelines with glimepiride dosing, monitoring, and adverse effect management.